GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
1.5300
-0.0100 (-0.65%)
As of 1:06PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.5400
Open1.5000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.5000 - 1.5400
52 Week Range0.0838 - 3.1000
Volume13,384
Avg. Volume197,921
Market Cap92.27M
Beta (3Y Monthly)-4.64
PE Ratio (TTM)3.14
EPS (TTM)0.4880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 minutes ago

    KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019

    DALLAS, March 20, 2019 -- via OTC PR WIRE --   Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company plans to publish its.

  • GlobeNewswire2 days ago

    KALY Initiates Phase Two Cannabis Extract COPD Treatment Study

    DALLAS, March 18, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced Professor Jeffry Osbourn, Ph.D.,.

  • GlobeNewswire8 days ago

    Generex Biotechnology Announces the Appointment of Chief Commercial Officer

    MIRAMAR, FL, March 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is proud to announce the appointment of Lance Goudzwaard as the Chief Commercial Officer for NuGenerex Distribution Solutions (NDS), the company’s wholly-owned subsidiary. Mr. Goudzwaard will be responsible for the delivery and operation of the management services organization (MSO) platform that is currently operational in five states, with an aggressive growth strategy designed to expand the model to 27 states in the next several months. Mr. Goudzwaard will also focus on building and developing our durable medical equipment (DME) service offering called DME-IQÔ, a software system being introduced to the orthopedic market with turnkey services to support the development and management of compliant and profitable in-office DME programs.

  • GlobeNewswire12 days ago

    KALY Cannabis Patent Featured In PURA Report On Progress Toward $5 Million Sales Goal

    DALLAS, March 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced the company’s recent advances developing a CBD extract for infusion into a beverage at a 25 mg concentration were featured in a report published yesterday by Puration, Inc. (PURA) (“PURA”).  PURA yesterday reported recent progress toward the company’s $5 million 2019 sales goal.  The report included an overview of KALY’s role using its patented extraction process to develop a CBD extract that will sustain suspension in a beverage at a consistent concentrate level of 25 mg.  The first target beverage for the 25 mg CBD concentrate beverage is a private labeled health water for Generex Biotechnology (GNBT).

  • GlobeNewswire12 days ago

    Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Appointment of Vice President of Business Strategy

    Industry Veteran John P. Sentman to Lead Strategic Sales and Partnering MIRAMAR, FL, March 08, 2019 -- via NEWMEDIAWIRE -- Olaregen Therapeutix, a subsidiary of Generex.

  • Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
    GlobeNewswire13 days ago

    Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest

    DALLAS, March 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival.

  • GlobeNewswire19 days ago

    Generex Investor Conference Call Now Available Online

    MIRAMAR, FL, March 01, 2019 -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced.

  • GlobeNewswire22 days ago

    PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019

    DALLAS, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Puration, Inc. (PURA) today announced an upcoming analyst update report expected to be published this Thursday, February 28, 2019.  The report expected on Thursday will be a second update from Goldman Small Cap Research which initiated analyst coverage in October last year and published a first update in November of last year confirming a Speculative Buy and $0.25 Target PPS.  The company has since the first update signed additional contracts and launched an all new formulation and packaging of its EVERx CBD Sports Water.  Earlier today, the company previewed a major coming announcement regarding its EVERx CBD Sports Water planned for release later this week. The previewed announcement expected later this week is separate from the Analyst Report update planned for release on Thursday this week.  The update report is anticipated to include an assessment of PURA’s $1.5 million contract with Generex Biotechnology (GNBT) to produce custom, private ladled, CBD Infused water for Generex.  PURA is working with Kali-Extracts (KALY) to develop the customer CBD extract formulation for infusion into the water produced for Generex.

  • GlobeNewswire22 days ago

    Reminder: Investor Conference Call Today, February 26, 2019; Management to Provide Update on Initiatives & Strategic Plans, Call-in Details

    MIRAMAR, FL, Feb. 26, 2019 -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced.

  • GlobeNewswire27 days ago

    KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study

    DALLAS, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The first preview was published on February 5, 2019.  The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

  • GlobeNewswire29 days ago

    Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)

    MIRAMAR, FL, Feb. 19, 2019 -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to.

  • GlobeNewswirelast month

    Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern

    MIRAMAR, FL, Feb. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), today announced an agenda for the investor conference call to be presented Tuesday, February 26, at 11:00 AM. Eastern time. Joseph Moscato, President & Chief Executive Officer of Generex will provide a February update on the progress and status of the company’s strategic plans and operations. Mr. Moscato will provide new information on current and planned acquisitions of products and businesses that bolster and expand the capabilities and service offerings of the NuGenerex family of subsidiary companies, continuing the Generex mission to provide integrated solutions for patients and the healthcare community.

  • GlobeNewswirelast month

    Generex Announces Appointment of Marshal Schictman, Esq. as Executive Vice President General Counsel and Corporate SEC Attorney

    MIRAMAR, FL, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (GNBT) is pleased to announce that Marshal Schictman, Esq. Mr. Schictman has practiced law for over 16 years, with wide-ranging expertise in the areas of corporate, securities, and finance law, primarily in the areas of capital markets and securities trading.

  • GlobeNewswirelast month

    KALY – Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview

    DALLAS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a preview of the recently announced long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

  • GlobeNewswirelast month

    Generex Biotechnology Responds to Demand for Payment

    MIRAMAR, FL, Feb. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) provided a response to the demand for payment from Alpha Capital Anstalt. As reported in our 8-K filed on January 31, 2019, Generex (GNBT) received a demand, on January 25, 2019, from Alpha Capital for immediate repayment of Generex’s Note Due October 26, 2019 (“Note”), coupled with an intent to sue Generex if payment was not made. Although Generex has not defaulted in any payment, Alpha Capital called a default under the Note based on terms stating that Generex must up-list to the NASDAQ market within a specified time.  If litigation ensues, Generex intends to assert affirmative defenses that Alpha took aggressive actions to intentionally harm Generex as the company executed on it plan to up-list to NASDAQ, intentionally frustrating key elements necessary for the up-listing.  CEO Joseph Moscato personally guaranteed the instrument with his own personal shares.

  • ACCESSWIRE2 months ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • PR Newswire2 months ago

    KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview

    DALLAS , Feb. 1, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced a preview presentation scheduled for next week, on Tuesday, ...

  • GlobeNewswire2 months ago

    KALY Releases Update Highlighting Potential In $14 Billion COPD Treatment Market and Additional Pharmaceutical Markets

    DALLAS, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today released a corporate update that includes the latest on KALY’s developments with Puration, Inc, (PURA) (“PURA”) and Generex Biotechnology, Inc. (GNBT), the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD), and other updates.

  • GlobeNewswire2 months ago

    Generex Biotechnology Announces Investor Conference Call Scheduled for February 26, 2019

    MIRAMAR, FL, Jan. 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT), today announced that it will hold a conference call on Tuesday, February 26th at 11:00 am to update investors on the completed share dividend for NuGenerex Immuno-Oncology (NGIO), as well as detailed plans for listing the shares on a public exchange. Generex will also provide details on the acquisition and integration of Fuse Medical, Pantheon Medical, and MediSource Partners, three companies that manufacture and distribute surgical and biologic products for orthopedic surgeons and podiatrists, many of which are members of the Nugenerex Distribution Solutions MSO. Joseph Moscato, Generex President & Chief Executive Officer, will discuss the company’s financing plans related to these and other, soon to be announced acquisitions that will enable Generex Biotechnology to augment the company’s product portfolio, further grow its provider networks, and expand its ancillary healthcare service offerings.

  • GlobeNewswire2 months ago

    KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week

    DALLAS, Jan. 25, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online corporate update scheduled.

  • GlobeNewswire2 months ago

    Generex Launches DME-IQ, the “Smart Solution” for In-Office Management of Durable Medical Equipment

    MIRAMAR, FL, Jan. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT)  (http://www.otcmarkets.com/stock/GNBT/quote) announced today that its wholly-owned subsidiary NuGenerex Distribution Solutions 2, LLC (NDS) has launched DME-IQ, a novel service for physicians who manage in-office distribution of durable medical equipment (DME). DME-IQ supports the development and management of compliant and profitable in-office DME programs.  DME-IQ focuses on several key areas, which include negotiating on behalf of the physicians with key vendors to decrease the Cost of Goods (COG’s), increasing insurance collections by providing oversight of the coding during the billing process, providing the necessary personnel to manage the appeals processes, and ensuring compliance with state and federal regulations.

  • GlobeNewswire2 months ago

    Generex Subsidiary NuGenerex Diagnostics Announces CE-Mark Certification for its Rapid Point-of-Care Express II Syphilis Treponemal Assay

    Commercialization of medical devices in the European Union requires meeting the regulatory guidelines of the European Medical Devices Directive (MDD) and fulfillment of those requirements allows a device to carry the “CE-Mark” as verification of its diagnostic authenticity. After completing rigorous test validation and submission of an application to the European Union, NuGenerex Diagnostics is pleased to announce that the CE Mark Certification for its The Express II Syphilis Treponemal Assay has been granted.

  • GlobeNewswire2 months ago

    Generex Announces REVISED Record Date for NuGenerex Immuno-Oncology Stock Dividend

    MIRAMAR, FL , Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has REVISED the record date for the previously announced dividend to Generex shareholders of shares in our wholly-owned subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express). The Record Date for the determination of the holders of the Company’s common stock entitled to participate in the dividend will now be January 30, 2019.  The dividend Payment Date remains February 25, 2019. The Company believes that the ex-dividend date will be Monday, January 28, 2019 by application of FINRA Uniform Practice Code rules which provide ex-dividend date for dividends of less than 25 percent of the value a company’s common stock is the second business day prior to the record date.

  • GlobeNewswire2 months ago

    Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans

    MIRAMAR, FL, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to provide the investment community with a review of the many accomplishments achieved in 2018, with a vision for growth in 2019 by Generex CEO Joseph Moscato. At the end of 2017, Generex formed a new, wholly-owned subsidiary, NuGenerex Distribution Solutions, LLC (NDS), completing the initial organizational restructuring of the company. In January 2018, NDS acquired Empire State Pharmacy LLC in New York and Grainland Pharmacy LLC in Kansas, commencing the Company’s strategic plans to establish itself as a presence in the U.S. direct-to-consumer pharmaceuticals business.

  • GlobeNewswire2 months ago

    Kali-Extracts and Puration Announce First Ever 25 mg CBD Extract Formulation For Beverage Infusion

    DALLAS, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) and Puration, Inc, (PURA) (“PURA”) today announced a new 25 mg CBD Extract formulation for beverage infusion.  KALY owns and manages a patented cannabis extraction process.  PURA has licensed the KALY patent for beverage infusion.  PURA currently produces EVERx CBD Sports Water infused with 10 mg of CBD.  Together KALY and PURA are designing a new private labeled CBD infused beverage for Generex Biotechnology, Inc. (GNBT).